Seeking Alpha
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

An Interview With Cellceutix CEO Leo Ehrlich

It has been more than one year since I have published an interview with Cellceutix (OTCPK:CTIX) Chief Executive Officer Leo Ehrlich and that article is now exclusively for Seeking Alpha Pro members. Given the litany of developments at the young biotech since September 2013, it was high time that I scheduled a conversation with Mr. Ehrlich to discuss the happenings and share with the investment community.

For those unfamiliar with Cellceutix, the company has a portfolio of more than a dozen compounds, headed by anti-cancer drug Kevetrin, anti-psoriasis drug Prurisol and Brilacidin, which is in a novel class of compounds in the Cellceutix portfolio called "defensin-mimetics." In order to provide a comprehensive report, it's necessary to provide a somewhat brief description on these compounds and where they stand today for some background for the interview.


Kevetrin, a small molecule, is a novel class of chemistry that was… Read More …